Bio-Techne said consolidated net sales for the quarter ended December 31, 2024 were $297.0 million, an increase of 9% compared to the same prior year period, and consolidated net earnings were $34.9 million compared to $27.5 million in the prior year quarter.

10-QQuarterly reportFiled Feb 6, 2025Period of report Dec 31, 2024Summary published (UTC) Oct 11, 2026

Key points

AI summary

Bio-Techne said consolidated net sales for the quarter ended December 31, 2024 were $297.0 million, an increase of 9% compared to the same prior year period, and consolidated net earnings were $34.9 million compared to $27.5 million in the prior year quarter.
The company said consolidated gross margin for the quarter was 65.3% compared to 64.8% in the same prior year period, and adjusted gross margin was 70.5% compared to 69.7% in the prior year quarter. It attributed the change primarily to fluctuations in product mix.
Bio-Techne said net earnings for the 6 months ended December 31, 2024 decreased to $68.5 million from $78.5 million in the same prior year period, citing restructuring and restructuring-related costs as factors. It added that cash generated from operating activities for the period was $148.2 million compared to $142.5 million in the prior year period.
The company said it must acquire the remaining 80.1% of Wilson Wolf on December 31, 2027, and the second option payment of approximately $1 billion plus potential contingent consideration is expected to occur between fiscal 2026 and 2028.

Key figures

Quarter ended December 31, 2024

Revenue: $297M
Operating income: $47M
Net income: $35M
EPS: $0.22
Gross profit: $194M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Quarterly net sales $297.0 million, net earnings $34.9 million

Bio-Techne said consolidated net sales for the quarter ended December 31, 2024 were $297.0 million, an increase of 9% compared to the same prior year period, and consolidated net earnings were $34.9 million compared to $27.5 million in the prior year quarter.

Source · Based on the MD&A text of the filing

Quarterly gross margin 65.3%, adjusted 70.5%

The company said consolidated gross margin for the quarter was 65.3% compared to 64.8% in the same prior year period, and adjusted gross margin was 70.5% compared to 69.7% in the prior year quarter. It attributed the change primarily to fluctuations in product mix.

Source · Based on the MD&A text of the filing

6-month net earnings $68.5 million, operating cash flow $148.2 million

Bio-Techne said net earnings for the 6 months ended December 31, 2024 decreased to $68.5 million from $78.5 million in the same prior year period, citing restructuring and restructuring-related costs as factors. It added that cash generated from operating activities for the period was $148.2 million compared to $142.5 million in the prior year period.

Source · Based on the MD&A text of the filing

Wilson Wolf remaining stake 80.1% acquisition obligation

The company said it must acquire the remaining 80.1% of Wilson Wolf on December 31, 2027, and the second option payment of approximately $1 billion plus potential contingent consideration is expected to occur between fiscal 2026 and 2028.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.